82128-11-8 Usage
Nitrile derivative
The compound is derived from nitriles, which are molecules containing a triple bond between carbon and nitrogen atoms.
Trifluoromethyl group
The presence of a CF3 group (three fluorine atoms bonded to a carbon atom) contributes to the compound's stability and reactivity.
Building block in organic synthesis
The compound is often used as a starting material or intermediate in the synthesis of more complex organic molecules.
Versatile properties
Due to its unique structure and functional groups, the compound can be used in various chemical reactions and transformations.
Pharmaceutical research
The compound has potential applications in the development of new drugs and therapeutic agents.
Crop protection agents
It may be used in the development of chemicals that protect crops from pests and diseases.
Materials science
The compound's unique structure and properties make it a potential candidate for use in the development of new materials with specific functions or characteristics.
Interesting target for further studies
The compound's structure and functional groups make it an attractive subject for further chemical and pharmaceutical research to explore its potential applications and properties.
Check Digit Verification of cas no
The CAS Registry Mumber 82128-11-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,1,2 and 8 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 82128-11:
(7*8)+(6*2)+(5*1)+(4*2)+(3*8)+(2*1)+(1*1)=108
108 % 10 = 8
So 82128-11-8 is a valid CAS Registry Number.
82128-11-8Relevant articles and documents
SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1
-
Page/Page column 1074, (2018/01/20)
The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
Improved glucose tolerance in rats treated with oxazolidinediones
Schnur,Morville
, p. 770 - 778 (2007/10/02)
-
